Platelet-Derived Shed CD31 Detection via Domain-Specific Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting soluble forms of CD31 in plasma are inadequate as they cannot distinguish between different forms, leading to inconclusive results in diagnosing atherothrombosis and autoimmune diseases, as they fail to differentiate between lymphocyte-derived, endothelial-derived, and platelet-derived shed CD31.
Innovation Solution
Development of a method involving specific antibodies that bind to epitopes unique to each form of CD31, allowing for the precise detection and quantification of platelet-derived shed CD31 by recognizing the 6th Ig-like domain, which is not present in lymphocyte-derived forms, enabling discrimination from the soluble splice variant.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If commercially available kits are used to detect total circulating CD31, then detection of soluble CD31 is achieved, but diagnostic accuracy is insufficient due to inability to differentiate between different CD31 forms
Solution Approach 1:
The invention segments the detection of soluble CD31 into distinct forms by using antibodies that specifically recognize different domains. The method separates detection of platelet-derived shed CD31 (containing 6th Ig-like domain) from other forms (lacking 6th domain or containing intracellular domain), enabling precise differentiation and accurate diagnosis without requiring complex multi-step procedures.
Solution Approach 2:
The invention introduces domain-specific antibodies as intermediaries to differentiate between CD31 forms. Antibodies targeting the 6th Ig-like domain serve as specific mediators to identify platelet-derived shed CD31, while antibodies targeting the intracellular domain identify other forms. These intermediary antibodies enable precise detection and differentiation without direct complex analysis of the CD31 molecules themselves.
2Measurement precision
If domain-specific antibodies are used to differentiate CD31 forms, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The detection assay is segmented into specific domain-targeting components. Rather than using a single complex reagent, the method employs simplified domain-specific antibodies that target either the 6th Ig-like domain or the intracellular domain. This segmentation allows precise discrimination of CD31 forms while maintaining assay simplicity through modular, specific binding interactions.
3Ease of operation
If total soluble CD31 is measured without differentiation, then ease of operation is maintained, but loss of information occurs regarding specific CD31 forms
Solution Approach 1:
The invention extracts specific information about CD31 forms by using antibodies that selectively bind to distinctive domains. The 6th Ig-like domain-specific antibody extracts information about platelet-derived shed CD31, while the intracellular domain-specific antibody extracts information about other forms. This extraction approach maintains operational simplicity while preventing information loss about specific CD31 forms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate differentiation of soluble CD31 forms, providing a diagnostic tool for thrombotic and inflammatory conditions by quantifying platelet-derived shed CD31, thereby improving diagnostic accuracy and enabling targeted treatments.
Implementation Method 1
specific antibodies that bind to epitopes unique to each form of CD31, allowing for the precise detection and quantification of platelet-derived shed CD31 by recognizing the 6th Ig-like domain
Data Source
AI summary
The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.